OTSKY News and Press, Otsuka Holdings Co. Ltd. ADR From 11/20/23

2023-11-20 11:18:10 ET More on Medtronic Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings Medtronic Stock Is Simply Too Cheap To Ignore Medtronic Faces Potential Decline Despite Financial Strength Medtronic Q2 2024 Earnings Preview ...

2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...

2023-08-24 06:59:36 ET More on Medtronic Medtronic plc ( MDT ) Q1 2024 Earnings Call Transcript Medtronic plc 2024 Q1 - Results - Earnings Call Presentation Medtronic: Dark Clouds Are Clearing - Outperformance Ahead Medtronic: MiniMed 780G Could Inspire G...

2023-04-13 15:36:07 ET German biotech Atai Life Sciences ( NASDAQ: ATAI ) added 12% Thursday after announcing investigators have dosed the first participant in a Phase 1 study for PCN-101, a candidate targeted at treatment-resistant depression (TRD). Atai ( ATAI ) comp...

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...

Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...

The success of a pivotal study of Rexulti in Alzheimer's-associated agitation brings an underserved market worth $1 billion or more per year into reach. First quarter results saw better-than-expected sales growth and margins, but the launch of Vyepti continues to underwhelm. In ad...

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...

Centessa Pharmaceuticals (NASDAQ:CNTA) stock fell ~11% premarket June 2, after the said it will discontinue developing lixivaptan for a type of kidney disease. The company will discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) including both a...

Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth. The current share price is very undervalued considering the long term growth prospects. For further details see: Takeda Pharmac...